Barclays PLC purchased a new position in Belite Bio in the third quarter valued at approximately $223,000.

Source: https://www.americanbankingnews.com/2023/02/23/belite-bio-nasdaqblte-sees-large-volume-increase-2.html

Equities research analysts predict that Belite Bio will post -1.27 earnings per share for the current fiscal year.

Source: https://www.etfdailynews.com/2023/10/01/belite-bio-inc-nasdaqblte-short-interest-up-17-9-in-september/

On average, equities research analysts forecast that Belite Bio will post -0.87 EPS for the current fiscal year.

Source: https://www.etfdailynews.com/2023/07/28/belite-bio-nasdaqblte-rating-reiterated-by-benchmark/

SVB Securities initiated coverage on shares of Belite Bio in a research note on Wednesday, July 26th.

Source: https://www.americanbankingnews.com/2023/08/24/belite-bio-nasdaqblte-shares-down-7-3.html